Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: A retrospective cohort study

BMC Pharmacology and Toxicology

Volumn 14, Issue , 2013, Pages

  Hall, Ronald G ^a,b   Hazlewood, Kathleen A ^a,f   Brouse, Sara D ^a,g   Giuliano, Christopher A ^a,h   Haase, Krystal K ^a   Frei, Chistopher R ^c   Forcade, Nicolas A ^c,i   Bell, Todd ^d   Bedimo, Roger J ^e   Alvarez, Carlos A ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF WYOMING SCHOOL OF PHARMACY   (United States)

^g UNIVERSITY OF KENTUCKY   (United States)

^h WAYNE STATE UNIVERSITY   (United States)

ⁱ Landstuhl Regional Medical Center   (United States)

Author keywords

Adverse events; Dosing; MRSA; Nephrotoxicity; Obesity; Vancomycin; Weight

Indexed keywords

AMINOGLYCOSIDE; CONTRAST MEDIUM; CREATININE; HYPERTENSIVE FACTOR; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOODSTREAM INFECTION; BODY WEIGHT; CATHETER INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG MONITORING; FEMALE; GASTROINTESTINAL INFECTION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LOW DRUG DOSE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTICENTER STUDY; NEPHROTOXICITY; OSTEOMYELITIS; PATIENT CARE; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; TREATMENT DURATION; UROGENITAL TRACT INFECTION; AGED; BACTEREMIA; CHEMICALLY INDUCED DISORDER; HOSPITAL; KIDNEY DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; STAPHYLOCOCCUS INFECTION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BODY WEIGHT; FEMALE; HOSPITALS; HUMANS; KIDNEY DISEASES; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

MLCS; MLOWN;

EID: 84879820628     PISSN: 20506511     EISSN: None     Source Type: Journal    
DOI: 10.1186/2050-6511-14-12     Document Type: Article

References (24)

1. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006, 166:2138-2144. 10.1001/archinte.166.19.2138, 17060545.
2. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008, 52:3315-3320. 10.1128/AAC.00113-08, 2533486, 18591266.
3. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004, 42:2398-2402. 10.1128/JCM.42.6.2398-2402.2004, 427878, 15184410.
4. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006, 44:3883-3886. 10.1128/JCM.01388-06, 1698298, 16957043.
5. Tenover FC, Moellering RC. The rationale for revising the clinical and laboratory standards institute vancomycin minimal inhibitory concentration interpretive criteria for staphylococcus aureus. Clin Infect Dis 2007, 44:1208-1215. 10.1086/513203, 17407040.
6. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009, 66:82-98. 10.2146/ajhp080434, 19106348.
7. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007, 29:1107-1115. 10.1016/j.clinthera.2007.06.014, 17692725.
8. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009, 49:507-514. 10.1086/600884, 19586413.
9. Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med 2010, 123:1143-1149. 10.1016/j.amjmed.2010.07.025, 21183005.
10. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011, 52:975-981. 10.1093/cid/cir124, 21460309.
11. Hall RG, Giuliano CA, Haase KK, et al. Empiric guideline-recommended weight based dosing and mortality in methcillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study. BMC Infect Dis 2012, 12:104. 10.1186/1471-2334-12-104, 3532187, 22540223.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41. 10.1159/000180580, 1244564.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383. 10.1016/0021-9681(87)90171-8, 3558716.
14. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991, 115:585-590.
15. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents 1999, 11:7-12. 10.1016/S0924-8579(98)00060-0, 10075272.
16. Zhang H, Singer B. Recursive partitioning in the health sciences 1999, New York: Springer.
17. Rhee JY, Kwon KT, Ki HK, et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock 2009, 31:146-150. 10.1097/SHK.0b013e318182f98f, 18636041.
18. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004, 38:1673-1681. 10.1086/420818, 15227611.
19. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005, 41:S341-S353. 10.1086/431675, 16080072.
20. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005, 49:2260-2266. 10.1128/AAC.49.6.2260-2266.2005, 1140485, 15917519.
21. Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009, 48:203-212. 10.1086/595686, 19072714.
22. Downs NJ, Neihart RE, Dolezal JM, Hodges GR. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 1989, 149:1777-1781. 10.1001/archinte.1989.00390080053013, 2764651.
23. Sorrell TC, Collignon PJ. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother 1985, 16:235-241. 10.1093/jac/16.2.235, 3934126.
24. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008, 52:1330-1336. 10.1128/AAC.01602-07, 2292536, 18227177.